Abciximab provides cost-effective survival advantage in high-volume interventional practice
Titel:
Abciximab provides cost-effective survival advantage in high-volume interventional practice
Auteur:
Kereiakes, Dean J. Obenchain, Robert L. Barber, Beth L. Smith, Andrew McDonald, Mark Broderick, Thomas M. Runyon, John Paul Shimshak, Thomas M. Schneider, John F. Hattemer, Charles R. Roth, Eli M. Whang, David D. Cocks, Douglas Abbottsmith, Charles W.